Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELIC: Thawed Plasma in COVID-19
NCT04723589Phase 2Withdrawn
- Sponsor
- University of Alabama at Birmingham
- Start
- Apr 2021
- Primary completion
- Apr 2021
- Modality
- Recombinant Proteins and Enzymes, Tissue Cells
01
Overview
Phase 2, randomised, open-label trial of thawed plasma in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by University of Alabama at Birmingham. Primary endpoints: Number of participants completing plasma infusion for COVID-19 at 30 days and Number of participants intubated at 30 days. Planned start Apr 2021; status: withdrawn.
02
Drugs
thawed plasma
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04723589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04723589.